Cabiralizumab [1613144-80-1]

TargetMol Chemicals

Cabiralizumab

9

Antibody

Research Use Only

Cabiralizumab

Cabiralizumab (FPA 008), an anti-CSF1R monoclonal antibody (MAb), promotes T cell infiltration and boosts antitumor immune responses. It also prevents osteoclast activation, thereby inhibiting bone destruction, and is utilized in rheumatoid arthritis (RA) research. Additionally, Cabiralizumab can be paired with Nivolumab in lung cancer studies [1] [2].

3 years

-20°C

12352203